Scott J. Genshaft

Scott J. Genshaft

Auto-generated profile, based on publicly available information

Scott J. Genshaft

Division of Interventional Radiology, Department of Radiology, David Geffen School of Medicine at the University of California, Los Angeles, CA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
LCLucas Cusumano
Lucas Cusumano
SSSparks Sparks
Sparks Sparks
KMKara E. Masterson
Kara E. Masterson
SGScott J. Genshaft
Scott J. Genshaft
APAdam N. Plotnik
Adam N. Plotnik
SPSiddharth A. Padia
Siddharth A. Padia
To report the 24-month outcomes and subgroup analysis evaluating the safety and effectiveness of the genicular artery embolization (GAE) for the treatment of symptomatic knee osteoarthritis (OA). Forty participants with symptomatic moderate to severe knee OA from a single-center, single-arm prospective trial of GAE were included in this study. Abnormal genicular artery neovascularity was identified at the subject's focal knee pain with digital subtraction angiography and cone-beam computed tomography. Embolization was performed with 100-μm microspheres. The primary end point was treatment effectiveness as measured by sustained improvement in OA symptoms at 24 months, quantified using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Treatment success was defined as ≥50% decrease in WOMAC relative to baseline. Clinical outcomes were assessed with mean age of 66.0 ± 8.1 years and BMI of 30.1 ± 6.2 kg/m2. Two of the forty (5.0%) patients were lost to follow up. Overall, 18 of 38 (47.4%) patients demonstrated ≥50% reduction in WOMAC at 24 months. In the subset of patients with initial clinical success at 12 months, 18 of 25 (72.0%) reported sustained clinical success at 24 months. Seven of 25 (28.0%) had symptom recurrence between 12 and 24 months and were determined to be clinical failures. All treatment-related adverse events occurred within 12 months following GAE, without additional events after 12 months. GAE is effective in achieving sustained symptom relief related to moderate to severe knee OA for up to 24 months with an acceptable safety profile.

1 November 2015 in Journal of Thoracic Imaging
Verified
Journal Article
Closed access
RSRobert Suh
Robert Suh
SGScott J. Genshaft
Scott J. Genshaft
JKJacobo Kirsch
Jacobo Kirsch
JKJeffrey P. Kanne
Jeffrey P. Kanne
JCJonathan Chung
Jonathan Chung
TMTan-Lucien H. Mohammed
Tan-Lucien H. Mohammed
Portable chest radiography is a fundamental and frequently utilized examination in the critically ill patient population. The chest radiograph often represents a timely investigation of new or rapidly evolving clinical findings and an evaluation of proper positioning of support tubes and catheters. Thoughtful consideration of the use of this simple yet valuable resource is crucial as medical cost containment becomes even more mandatory. This review addresses the role of chest radiography in the intensive care unit on the basis of the existing literature and as formed by a consensus of an expert panel on thoracic imaging through the American College of Radiology. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

1 April 2015 in Academic Radiology
Verified
Journal Article
Closed access
AOAndrea S. Oh
Andrea S. Oh
CACorey W. Arnold
Corey W. Arnold
SVSitaram Vangala
Sitaram Vangala
WWW. Dean Wallace
W. Dean Wallace
SGScott J. Genshaft
Scott J. Genshaft
DADenise R. Aberle
Denise R. Aberle

1 May 2021 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
SPS. Padia
S. Padia
APA. Plotnik
A. Plotnik
GBG. Blumstein
G. Blumstein
ASAlexandra I. Stavrakis
Alexandra I. Stavrakis
EZE. Zeegen
E. Zeegen
SGS. Genshaft
S. Genshaft

20 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALAaron Elliott Lisberg
Aaron Elliott Lisberg
Bin LiuBin Liu
Bin Liu
RSRamin Salehi-Rad
Ramin Salehi-Rad
JLJay Lee
Jay Lee
LTLinh Tran
Linh Tran
SDSteven M. Dubinett
Steven M. Dubinett
TPS9135 Background: Effective immunotherapy options are lacking for patients with advanced non-small cell lung cancer (NSCLC) who progress on a programmed cell death-(ligand)1 [PD-(L)1] inhibitor and for those that are epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement positive after progression on tyrosine kinase inhibitor (TKI) therapy. One potential approach to improve immune checkpoint efficacy in these patient populations is to promote cytolytic T cell infiltration into tumors. This can be accomplished via in situ vaccination with functional antigen presenting cells (APCs) which can take advantage of the full repertoire of tumor antigens and convert the tumor into a lymph node-like environment promoting both local and systemic T cell activation. The chemokine CCL21 promotes co-localization of naive T cells and antigen-experienced dendritic cells (DCs) to facilitate T cell activation. Our preclinical studies and phase I trial of intratumoral (IT) administration of DC genetically modified to overexpress CCL21 (CCL21-DC) revealed augmentation of tumor antigen presentation in situ, resulting in systemic antitumor immunity. However, increased PD-L1 expression was observed in some patient tumors, suggesting that tumor-mediated impairment of T cell function may be forestalling a more robust CCL21-DC mediated antitumor response. Similarly, improved PD-(L)1 inhibitor efficacy may be possible with enhanced T cell infiltration and augmented APC function following IT CCL21-DC. Therefore, we are conducting a phase I trial, combining IT CCL21-DC with pembrolizumab in patients with advanced NSCLC that are either (1) EGFR/ALK wild-type after progression on a PD-(L)1 inhibitor or (2) EGFR/ALK mutant after progression on TKI therapy. Methods: Phase I, dose-escalating, multi-cohort trial followed by dose expansion. Maximum of 24 patients (9-12 escalation + 12 expansion) with stage IV NSCLC will be evaluated who have tumors accessible for IT injection and are either (1) EGFR/ALK wild-type after progression on a PD-(L)1 inhibitor or (2) EGFR/ALK mutant after progression on TKI therapy. Three IT injections of autologous CCL21-DC (days 0, 21, 42) will be concurrently administered with pembrolizumab, followed by q3wk pembrolizumab up to 1 year. Primary objective of dose escalation is safety and determination of maximum tolerated dose (MTD) of IT CCL21-DC (5x106, 1x107, or 3x107) when combined with pembrolizumab. Primary objective of dose expansion is objective response rate at MTD. Secondary objectives include adverse event profiling and determination of drug target activity by immune monitoring studies. This trial, NCT03546361, is currently open for enrollment. Clinical trial information: NCT03546361.